Current Challenges in Stem Cell Transplantation in Myelofibrosis

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Primary or post-ET/PV myelofibrosis is a Philadelphia-negative myeloproliferative neoplasm with poor prognosis.
• Allogeneic stem cell transplantation (ASCT) can cure myelofibrosis but carries significant toxicity.
• Recent advancements have improved ASCT outcomes, including less toxic conditioning and relapse prevention.

Purpose of the Study:

• To evaluate the role and justification of ASCT in treating myelofibrosis.
• To discuss the benefits and risks of ASCT in eligible patients.
• To highlight strategies for improving ASCT efficacy and reducing relapse.

Main Methods:

• Review of current literature and clinical practices regarding ASCT for myelofibrosis.
• Analysis of risk stratification scores (IPSS, DIPSS) for patient selection.
• Discussion of novel therapeutic approaches, including JAK2 inhibitors and adoptive immunotherapy.

Main Results:

• ASCT is a potentially curative option for myelofibrosis, particularly for intermediate-2 and high-risk patients.
• Improved ASCT outcomes are attributed to reduced conditioning toxicity and enhanced relapse prevention.
• Novel therapies like JAK2 inhibitors can optimize transplant preparation.

Conclusions:

• ASCT is justified for eligible myelofibrosis patients with expected survival less than 5 years.
• Careful consideration of the benefit/risk ratio, including patient-specific factors, is crucial.
• Ongoing research and therapeutic advancements continue to improve ASCT's role in myelofibrosis management.